D
Abeona Therapeutics Inc.
ABEO
$4.68
$0.235.17%
D
Sell
9/19/2024Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 9/19/2024 due to an increase in the volatility index and total return index.
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 9/19/2024 due to an increase in the volatility index and total return index.
E
Sell
9/3/2024Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 9/3/2024 due to a decline in the volatility index.
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 9/3/2024 due to a decline in the volatility index.
D
Sell
8/15/2024Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 8/15/2024 due to a significant increase in the solvency index, growth index and volatility index. Earnings per share increased from -$1.156 to -$0.2625, the quick ratio increased from 5.43 to 7.38, and operating cash flow increased 12.75% from -$14.54M to -$12.68M.
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 8/15/2024 due to a significant increase in the solvency index, growth index and volatility index. Earnings per share increased from -$1.156 to -$0.2625, the quick ratio increased from 5.43 to 7.38, and operating cash flow increased 12.75% from -$14.54M to -$12.68M.
E
Sell
7/29/2024Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 7/29/2024 due to a decline in the volatility index and valuation index.
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 7/29/2024 due to a decline in the volatility index and valuation index.
D
Sell
7/10/2024Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 7/10/2024 due to an increase in the volatility index.
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 7/10/2024 due to an increase in the volatility index.
E
Sell
6/21/2024Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 6/21/2024 due to a decline in the volatility index and total return index.
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 6/21/2024 due to a decline in the volatility index and total return index.
D
Sell
6/4/2024Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 6/4/2024 due to an increase in the valuation index, total return index and volatility index.
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 6/4/2024 due to an increase in the valuation index, total return index and volatility index.
E
Sell
4/25/2024Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 4/25/2024 due to a noticeable decline in the growth index, volatility index and solvency index. Operating cash flow declined 60.72% from -$5.75M to -$9.24M, the quick ratio declined from 6.65 to 4.07, and earnings per share declined from -$0.4773 to -$0.6457.
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 4/25/2024 due to a noticeable decline in the growth index, volatility index and solvency index. Operating cash flow declined 60.72% from -$5.75M to -$9.24M, the quick ratio declined from 6.65 to 4.07, and earnings per share declined from -$0.4773 to -$0.6457.
D
Sell
3/1/2024Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 3/1/2024 due to a large increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.17 to 0.07, and the quick ratio increased from 4.5 to 6.65.
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 3/1/2024 due to a large increase in the total return index, volatility index and solvency index. Debt to equity declined from 0.17 to 0.07, and the quick ratio increased from 4.5 to 6.65.
E
Sell
3/14/2023Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 3/14/2023 due to a decline in the volatility index.
D
Sell
2/23/2023Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and total return index.
D
Sell
11/17/2022Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 11/17/2022 due to a decline in the growth index, solvency index and volatility index. Debt to equity increased from 0.09 to 0.12, and the quick ratio declined from 1.68 to 1.52.
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 11/17/2022 due to a decline in the growth index, solvency index and volatility index. Debt to equity increased from 0.09 to 0.12, and the quick ratio declined from 1.68 to 1.52.
D
Sell
8/15/2022Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 8/15/2022 due to a large increase in the growth index, total return index and volatility index. Total revenue increased 189.02% from $346 to $1M, earnings per share increased from -$3.5877 to -$2.0799, and EBIT increased 34.35% from -$14.42M to -$9.47M.
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 8/15/2022 due to a large increase in the growth index, total return index and volatility index. Total revenue increased 189.02% from $346 to $1M, earnings per share increased from -$3.5877 to -$2.0799, and EBIT increased 34.35% from -$14.42M to -$9.47M.
D
Sell
5/16/2022Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 5/16/2022 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.4459 to -$0.1435, and operating cash flow increased 54.76% from -$30.26M to -$13.69M.
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 5/16/2022 due to an increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.4459 to -$0.1435, and operating cash flow increased 54.76% from -$30.26M to -$13.69M.
E
Sell
4/18/2022Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 4/18/2022 due to a major decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0719 to -$0.4459, operating cash flow declined 192.79% from -$10.33M to -$30.26M, and debt to equity increased from 0.02 to 0.04.
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 4/18/2022 due to a major decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0719 to -$0.4459, operating cash flow declined 192.79% from -$10.33M to -$30.26M, and debt to equity increased from 0.02 to 0.04.
D
Sell
3/7/2022Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 3/7/2022 due to a decline in the total return index and volatility index.
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 3/7/2022 due to a decline in the total return index and volatility index.
D
Sell
1/25/2022Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 1/25/2022 due to an increase in the volatility index.
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 1/25/2022 due to an increase in the volatility index.
D
Sell
1/7/2022Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 1/7/2022 due to a decline in the growth index, volatility index and total return index. EBIT declined 8.44% from -$13.72M to -$14.87M.
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 1/7/2022 due to a decline in the growth index, volatility index and total return index. EBIT declined 8.44% from -$13.72M to -$14.87M.
D
Sell
11/9/2021Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D from E+ on 11/09/2021.
Abeona Therapeutics Inc. (ABEO) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 2.12 to 1.85.
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 2.12 to 1.85.
D
Sell
7/29/2021Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 7/29/2021 due to an increase in the volatility index.
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 7/29/2021 due to an increase in the volatility index.
D
Sell
7/13/2021Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 7/13/2021 due to a decline in the volatility index.
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 7/13/2021 due to a decline in the volatility index.
D
Sell
6/22/2021Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 6/22/2021 due to an increase in the volatility index.
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 6/22/2021 due to an increase in the volatility index.
D
Sell
6/7/2021Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 6/7/2021 due to a decline in the volatility index, total return index and valuation index.
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 6/7/2021 due to a decline in the volatility index, total return index and valuation index.
D
Sell
5/18/2021Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 5/18/2021 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.1704 to -$0.17.
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 5/18/2021 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$0.1704 to -$0.17.
D
Sell
3/25/2021Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 3/25/2021 due to a large decline in the growth index, solvency index and total return index. EBIT declined 131.75% from -$6.25M to -$14.48M, earnings per share declined from -$0.0772 to -$0.1748, and total revenue declined 57.14% from $7M to $3M.
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 3/25/2021 due to a large decline in the growth index, solvency index and total return index. EBIT declined 131.75% from -$6.25M to -$14.48M, earnings per share declined from -$0.0772 to -$0.1748, and total revenue declined 57.14% from $7M to $3M.
D
Sell
8/11/2020Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 8/11/2020 due to a major increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.5199 to -$0.14, operating cash flow increased 28.39% from -$13.23M to -$9.48M, and EBIT increased 18.4% from -$15.3M to -$12.48M.
Abeona Therapeutics Inc. (ABEO) was upgraded to D from D- on 8/11/2020 due to a major increase in the growth index, solvency index and total return index. Earnings per share increased from -$0.5199 to -$0.14, operating cash flow increased 28.39% from -$13.23M to -$9.48M, and EBIT increased 18.4% from -$15.3M to -$12.48M.
D
Sell
11/13/2019Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 11/13/2019 due to an increase in the growth index. Earnings per share increased from -$0.4886 to -$0.35, and EBIT increased 26.39% from -$23.98M to -$17.65M.
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 11/13/2019 due to an increase in the growth index. Earnings per share increased from -$0.4886 to -$0.35, and EBIT increased 26.39% from -$23.98M to -$17.65M.
E
Sell
9/19/2019Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 9/19/2019 due to a major decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 3.19 to 2.45.
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 9/19/2019 due to a major decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 3.19 to 2.45.
D
Sell
7/1/2019Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 7/1/2019 due to a major decline in the growth index, solvency index and efficiency index. The quick ratio declined from 4.18 to 3.19, and total capital declined 5.7% from $134.05M to $126.41M.
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 7/1/2019 due to a major decline in the growth index, solvency index and efficiency index. The quick ratio declined from 4.18 to 3.19, and total capital declined 5.7% from $134.05M to $126.41M.
D
Sell
8/14/2018Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D from D+ on 8/14/2018 due to a major decline in the total return index, growth index and solvency index. Operating cash flow declined 121.02% from -$4.08M to -$9.02M, total revenue declined 68.48% from $2.6M to $819, and EBIT declined 39.44% from -$8.62M to -$12.01M.
Abeona Therapeutics Inc. (ABEO) was downgraded to D from D+ on 8/14/2018 due to a major decline in the total return index, growth index and solvency index. Operating cash flow declined 121.02% from -$4.08M to -$9.02M, total revenue declined 68.48% from $2.6M to $819, and EBIT declined 39.44% from -$8.62M to -$12.01M.
D
Sell
6/25/2018Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D+ from C- on 6/25/2018 due to a noticeable decline in the total return index.
Abeona Therapeutics Inc. (ABEO) was downgraded to D+ from C- on 6/25/2018 due to a noticeable decline in the total return index.
C
Hold
5/11/2018Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to C- from D+ on 5/11/2018 due to a large increase in the growth index, total return index and valuation index. Total revenue increased 1,108.37% from $215 to $2.6M, operating cash flow increased 23.36% from -$5.33M to -$4.08M, and earnings per share increased from -$0.1851 to -$0.1798.
Abeona Therapeutics Inc. (ABEO) was upgraded to C- from D+ on 5/11/2018 due to a large increase in the growth index, total return index and valuation index. Total revenue increased 1,108.37% from $215 to $2.6M, operating cash flow increased 23.36% from -$5.33M to -$4.08M, and earnings per share increased from -$0.1851 to -$0.1798.
D
Sell
5/10/2018Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D+ from D on 5/10/2018 due to a substantial increase in the total return index and growth index.
Abeona Therapeutics Inc. (ABEO) was upgraded to D+ from D on 5/10/2018 due to a substantial increase in the total return index and growth index.
D
Sell
3/16/2018Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D from D+ on 3/16/2018 due to a noticeable decline in the total return index and growth index. EBIT declined 63.19% from -$5.36M to -$8.75M, earnings per share declined from -$0.1323 to -$0.1887, and total revenue declined 1.83% from $219 to $215.
Abeona Therapeutics Inc. (ABEO) was downgraded to D from D+ on 3/16/2018 due to a noticeable decline in the total return index and growth index. EBIT declined 63.19% from -$5.36M to -$8.75M, earnings per share declined from -$0.1323 to -$0.1887, and total revenue declined 1.83% from $219 to $215.
D
Sell
9/20/2017Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D+ from D on 9/20/2017 due to an increase in the total return index and volatility index.
Abeona Therapeutics Inc. (ABEO) was upgraded to D+ from D on 9/20/2017 due to an increase in the total return index and volatility index.
D
Sell
9/5/2017Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D from D+ on 9/5/2017 due to a decline in the valuation index.
Abeona Therapeutics Inc. (ABEO) was downgraded to D from D+ on 9/5/2017 due to a decline in the valuation index.
D
Sell
8/15/2017Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D+ from D- on 8/15/2017 due to a noticeable increase in the growth index, total return index and efficiency index. Total revenue increased 16.67% from $186 to $217, and operating cash flow increased 14.94% from -$5.86M to -$4.98M.
Abeona Therapeutics Inc. (ABEO) was upgraded to D+ from D- on 8/15/2017 due to a noticeable increase in the growth index, total return index and efficiency index. Total revenue increased 16.67% from $186 to $217, and operating cash flow increased 14.94% from -$5.86M to -$4.98M.
D
Sell
3/31/2017Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 3/31/2017 due to a large decline in the efficiency index. Net income declined 166.84% from -$2.62M to -$7M.
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 3/31/2017 due to a large decline in the efficiency index. Net income declined 166.84% from -$2.62M to -$7M.
D
Sell
8/16/2016Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D from E+ on 8/16/2016 due to a large increase in the efficiency index and total return index.
Abeona Therapeutics Inc. (ABEO) was upgraded to D from E+ on 8/16/2016 due to a large increase in the efficiency index and total return index.
E
Sell
6/17/2016Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 6/17/2016 due to a decline in the volatility index.
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 6/17/2016 due to a decline in the volatility index.
D
Sell
6/1/2016Upgraded
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 6/1/2016 due to an increase in the volatility index.
Abeona Therapeutics Inc. (ABEO) was upgraded to D- from E+ on 6/1/2016 due to an increase in the volatility index.
E
Sell
5/17/2016Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 5/17/2016 due to a decline in the growth index, efficiency index and total return index. Earnings per share declined from -$0.0714 to -$0.1693, net income declined 136.92% from -$2.34M to -$5.54M, and total capital declined 3.04% from $67.72M to $65.66M.
Abeona Therapeutics Inc. (ABEO) was downgraded to E+ from D- on 5/17/2016 due to a decline in the growth index, efficiency index and total return index. Earnings per share declined from -$0.0714 to -$0.1693, net income declined 136.92% from -$2.34M to -$5.54M, and total capital declined 3.04% from $67.72M to $65.66M.
D
Sell
3/11/2016Downgrade
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index and total return index.
Abeona Therapeutics Inc. (ABEO) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the volatility index and total return index.
D
Sell
5/22/2015Upgraded
PlasmaTech Biopharmaceuticals, Inc. (PTBI) was upgraded to D from D- on 5/22/2015 due to an increase in the solvency index and volatility index. Debt to equity declined from 0.08 to 0, and the quick ratio increased from 3.99 to 6.53.
PlasmaTech Biopharmaceuticals, Inc. (PTBI) was upgraded to D from D- on 5/22/2015 due to an increase in the solvency index and volatility index. Debt to equity declined from 0.08 to 0, and the quick ratio increased from 3.99 to 6.53.
D
Sell
3/31/2015Downgrade
PlasmaTech Biopharmaceuticals, Inc. (PTBI) was downgraded to D- from D+ on 3/31/2015 due to a substantial decline in the efficiency index, valuation index and volatility index. Total capital declined 130.49% from -$17.11M to $5.22M.
PlasmaTech Biopharmaceuticals, Inc. (PTBI) was downgraded to D- from D+ on 3/31/2015 due to a substantial decline in the efficiency index, valuation index and volatility index. Total capital declined 130.49% from -$17.11M to $5.22M.
D
Sell
8/15/2014Downgrade
Access Pharmaceuticals Inc. (ACCP) was downgraded to D+ from C on 8/15/2014 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 47.06% from -$1.33M to -$703.
Access Pharmaceuticals Inc. (ACCP) was downgraded to D+ from C on 8/15/2014 due to a significant decline in the valuation index, efficiency index and growth index. EBIT declined 47.06% from -$1.33M to -$703.
C
Hold
3/28/2014Upgraded
Access Pharmaceuticals Inc. (ACCP) was upgraded to C from D on 3/28/2014 due to a significant increase in the efficiency index, total return index and volatility index. Net income increased 584.71% from -$157 to -$1.08M, and total capital increased 18.85% from -$12.44M to -$14.78M.
Access Pharmaceuticals Inc. (ACCP) was upgraded to C from D on 3/28/2014 due to a significant increase in the efficiency index, total return index and volatility index. Net income increased 584.71% from -$157 to -$1.08M, and total capital increased 18.85% from -$12.44M to -$14.78M.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
